21 An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumours (GCT): Results at the end of first stage (FM12GCT01)

A. Necchi; D. Magazzu’; A. Anichini; D. Raggi; P. Giannatempo; N. Nicolai; M. Colecchia; B. Paolini; E. Coradeschi; E. Tassi; G. Grazia; R. Mortarini; G. Calareso; E. Togliardi; F. Crippa; R. Salvioni; A. Gianni; P. Valagussa

doi:10.1016/s1569-9056(16)60023-4

21 An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumours (GCT): Results at the end of first stage (FM12GCT01)

European Urology Supplements ◽

10.1016/s1569-9056(16)60023-4 ◽

2016 ◽

Vol 15 (3) ◽

pp. e21

Author(s):

A. Necchi ◽

D. Magazzu’ ◽

A. Anichini ◽

D. Raggi ◽

P. Giannatempo ◽

...

Keyword(s):

Germ Cell ◽

Salvage Therapy ◽

Brentuximab Vedotin ◽

Germ Cell Tumours ◽

Phase 2 ◽

Single Group ◽

Open Label ◽

Phase 2 Study

Download Full-text

Faculty of 1000 evaluation for Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study.

F1000 - Post-publication peer review of the biomedical literature ◽

10.3410/f.718052125.793484801 ◽

2013 ◽

Author(s):

Steve Plaxe ◽

Kristy Ward

Keyword(s):

Germ Cell ◽

Children And Adolescents ◽

Salvage Treatment ◽

Germ Cell Tumours ◽

Phase 2 ◽

Single Institution ◽

Open Label ◽

Phase 2 Study ◽

Deep Hyperthermia

Download Full-text

Faculty Opinions recommendation of PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725357238.793504256 ◽

2015 ◽

Author(s):

Michele Spina

Keyword(s):

Salvage Therapy ◽

Hodgkin’S Lymphoma ◽

Brentuximab Vedotin ◽

Hodgkin's Lymphoma ◽

Phase 2 ◽

Single Centre ◽

Open Label ◽

Phase 2 Study

Download Full-text

Design of a Phase 2 STudy of Brentuximab Vedotin (SGN-35) as Salvage Therapy for Males with Chemoresistant Germ-Cell Tumors (GCT)

Annals of Oncology ◽

10.1093/annonc/mdu467.14 ◽

2014 ◽

Vol 25 ◽

pp. vi3

Author(s):

P. Giannatempo ◽

A. Anichini ◽

D. Raggi ◽

E. Cordareschi ◽

N. Nicolai ◽

...

Keyword(s):

Germ Cell ◽

Salvage Therapy ◽

Germ Cell Tumors ◽

Brentuximab Vedotin ◽

Phase 2 ◽

Phase 2 Study

Download Full-text

Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(13)70271-7 ◽

2013 ◽

Vol 14 (9) ◽

pp. 843-852 ◽

Cited By ~ 50

Author(s):

Rüdiger Wessalowski ◽

Dominik T Schneider ◽

Oliver Mils ◽

Verena Friemann ◽

Olga Kyrillopoulou ◽

...

Keyword(s):

Germ Cell ◽

Children And Adolescents ◽

Salvage Treatment ◽

Germ Cell Tumours ◽

Phase 2 ◽

Single Institution ◽

Open Label ◽

Phase 2 Study ◽

Deep Hyperthermia

Download Full-text

1123 Activity of pazopanib in chemoresistant patients with germ cell tumours (GCT): Early findings of the open-label, single-group, phase 2 pazotest-01 trial

European Urology Supplements ◽

10.1016/s1569-9056(14)61103-9 ◽

2014 ◽

Vol 13 (1) ◽

pp. e1123

Author(s):

A. Necchi ◽

L. Mariani ◽

P. Giannatempo ◽

N. Nicolai ◽

E. Farè ◽

...

Keyword(s):

Germ Cell ◽

Germ Cell Tumours ◽

Phase 2 ◽

Single Group ◽

Open Label

Download Full-text

PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(15)70013-6 ◽

2015 ◽

Vol 16 (3) ◽

pp. 284-292 ◽

Cited By ~ 127

Author(s):

Alison J Moskowitz ◽

Heiko Schöder ◽

Joachim Yahalom ◽

Susan J McCall ◽

Stephanie Y Fox ◽

...

Keyword(s):

Salvage Therapy ◽

Hodgkin’S Lymphoma ◽

Brentuximab Vedotin ◽

Hodgkin's Lymphoma ◽

Phase 2 ◽

Single Centre ◽

Open Label ◽

Phase 2 Study

Download Full-text

Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2 -amplified early stage breast cancer: a single-group, open-label, phase 2 study

The Lancet Oncology ◽

10.1016/s1470-2045(13)70384-x ◽

2013 ◽

Vol 14 (11) ◽

pp. 1121-1128 ◽

Cited By ~ 76

Author(s):

Stephen E Jones ◽

Rufus Collea ◽

Devchand Paul ◽

Scot Sedlacek ◽

Anne M Favret ◽

...

Keyword(s):

Breast Cancer ◽

Early Stage ◽

Early Stage Breast Cancer ◽

Phase 2 ◽

Single Group ◽

Open Label ◽

Phase 2 Study ◽

Open Label Phase

Download Full-text

Pazopanib in chemoresistant patients with germ cell tumors (GCT): Updated results of the open-label, single-group, phase 2 Pazotest-01 trial.

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.e15529 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. e15529-e15529 ◽

Cited By ~ 1

Author(s):

Patrizia Giannatempo ◽

Luigi Mariani ◽

Nicola Nicolai ◽

Elena Farè ◽

Daniele Raggi ◽

...

Keyword(s):

Germ Cell ◽

Germ Cell Tumors ◽

Phase 2 ◽

Single Group ◽

Open Label

Download Full-text

APACHE: An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab (D, MEDI4736), alone or in combination with Tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)

European Urology Supplements ◽

10.1016/s1569-9056(17)30282-8 ◽

2017 ◽

Vol 16 (3) ◽

pp. e373-e374

Author(s):

A. Necchi ◽

L. Mariani ◽

A. Anichini ◽

P. Giannatempo ◽

D. Raggi ◽

...

Keyword(s):

Germ Cell ◽

Germ Cell Tumors ◽

Phase 2 ◽

Open Label ◽

Programmed Death Ligand 1 ◽

Programmed Death ◽

Phase 2 Study ◽

Randomized Phase 2

Download Full-text

Apache: An open label, randomized, phase 2 study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.4547 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 4547-4547 ◽

Cited By ~ 4

Author(s):

Daniele Raggi ◽

Patrizia Giannatempo ◽

Luigi Mariani ◽

Maurizio Colecchia ◽

Giuseppina Calareso ◽

...

Keyword(s):

Germ Cell ◽

Germ Cell Tumors ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Randomized Phase 2

Download Full-text